Evicenter
MarkdownMedical informationP&T meetings
Ifezuntirgene inilparvovec (AMT-130)

Huntington's disease

Manufacturer
uniQure
Launch
Not announced
Last updated
291 sources

Clinical evidence

CT-AMT-130-01

62 evidence topics · 21 sources

Objective
Location and study date
United States study sites in the registry record
SiteCity
University of Alabama at Birmingham“Birmingham”
University of Arizona (Surgical Site Only)“Tucson”
University of California, San Francisco“San Francisco”
CenExel Rocky Mountain Clinical Research“Englewood”
Rush University Medical Center“Chicago”
Johns Hopkins University“Baltimore”
University of Michigan Department of Neurology“Ann Arbor”
Ohio State University“Columbus”
Vanderbilt University Medical Center“Nashville”
The University of Texas“Houston”
Virginia Commonwealth University VCU School of Medicine, Department of Neurology“Richmond”
University of Washington Medical Center“Seattle”
Study dates in the registry record
DateRegistry value
Study start (actual)“2019-09-06”
Primary completion (estimated)“2029-06”
Study completion (estimated)“2029-12”
Last update posted“2025-10-21”
Study dates in the original registry record, October 2019, superseded
Study design
Design fields in the current registry record
Randomized, triple-masked sequential design with crossover: registry version 33, October 2024, superseded
Eligibility criteria
Treatment
Study outcomes
Rationale for using adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Estimated total enrollment in the current registry record
FieldRegistry value
Enrollment (estimated)“43”
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Cohort 4 baseline characteristics
Characteristic (mean or %)AMT-130 high-dose Cohort 4 (n=6)
Sex, males (%)“16.7”
Age“43.7”
CAG repeats“44.5”
DCL = 3, 4 (%)“16.7, 83.3”
TFC“12.0”
Efficacy results
U.S. interim analysis: clinical measures against baseline, controls, and a TRACK-HD natural history cohort, June 2023
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations
Summary
  • Changed blinding and registry inconsistencies: the current ClinicalTrials.gov record lists allocation as non-randomized and masking as none (open label), while its official title describes a randomized, double-blind, sham control and open-label study. Version 1 (2019) listed a randomized, quadruple-masked design with an estimated enrollment of 26 and a blinded 18-month core period; version 33 (2024) listed a randomized, triple-masked design with an estimated enrollment of 37 and a blinded 12-month core period; the current record lists an estimated enrollment of 43. Cohort 4 is open-label.
  • Short randomized comparison: the sham comparison in Cohorts 1 and 2 covered the blinded 12-month period, after which sham participants could cross over. Four of the six control participants in the high-dose cohort crossed over and the other two did not meet the inclusion criteria, and interim analyses compared treated participants with control participants only up to 12 months and excluded efficacy data from crossover participants.
  • Small numbers: Cohorts 1 and 2 randomized 26 participants (six low dose, 10 high dose, 10 sham); Cohort 3 enrolled 12 and Cohort 4 six.
  • Safety as the primary outcome: the study is designed to establish safety and proof-of-concept, and the registered primary outcome is adverse events at 12 months.
  • Target engagement: the company states that CSF mutant huntingtin is not believed to be materially representative of mutant huntingtin in the targeted brain regions, and one commentary noted that there are no data on mutant HTT lowering.
  • Protocol changes: version 1 required ≥44 CAG repeats and an imitation surgery with bilateral partial thickness burr holes; the current record requires ≥40 CAG repeats and a simulated procedure with skin incisions only and no burr holes. Cohort 3 was first planned to study alternative stereotactic navigation systems and was redesigned to study perioperative immunosuppression.